Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI)
SES · USD · Healthcare · Drug Manufacturers - Specialty & Generic
$2.60 (+0.39%) as of
Key statistics
- Market cap
- 3.35B
- P/E (TTM)
- 16.25
- Forward P/E
- 10.00
- EPS (TTM)
- 0.1600
- Dividend yield
- 26.94%
- 52-week range
- 2.4500 – 3.7500
- Beta
- 0.46
- Revenue (TTM)
- 4.72B
- Profit margin
- 17.96%
- Volume
- 88.10k
About Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1915 and is based in Tianjin, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Tianjin, China
- Employees
- 3,890
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.